NervGen Pharma will be Webcasting on 11th July at VirtualInvestorConferences.com

NervGen Pharma

An announcement was made today by NervGen Pharma Corp. which is a regenerative medicine firm dedicated to the creation of ground-breaking solutions for the treatment of nerve damage & neurodegenerative diseases, that Ernest Wong, President, and Chief Executive Officer, will be presenting live at VirtualInvestorConferences.com on the 11th of July, 2019 at 10:30 AM.

This will be an interactive, live event where the investors are given the invitation to ask the firm questions in real-time. If the attendees are unable to join the event live on the day of the conference, there will be the availability of an archived webcast after the event.

It is suggested that investors pre-register & run the online system check to speed up the participation & receive updates about the event.

Virtual Investor Conferences is one of the top proprietary investor conference series which provides an interactive platform for publicly-traded firms to meet & present directly with investors.

Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services particularly designed for more effective Investor Access. Imitating the look & feel of on-site investor conferences, Virtual Investor Conferences integrate the leading-edge conferencing & investor communications capabilities with an all-inclusive global investor audience network.

NervGen, on the other hand, is restoring life’s potential by the creation of ground-breaking solutions for the treatment of nerve damage & neurodegenerative diseases. The firm is involved in the development of drugs for both multiple sclerosis and spinal cord injury.

NervGen has planned to initiate a Phase I human clinical trial for its major compound, NVG-291, at the beginning of 2020 under an Investigational New Drug application with the United States Food and Drug Administration.

NervGen is expanding NVG-291 for the treatment of multiple sclerosis and spinal cord injury as the firm believes these indications are significant opportunities in the market and have an intense impact on the quality of life & a high-cost burden to the healthcare system.